FDA experts turn thumbs down on PTC’s wobbly case for its Duchenne MD drug
After a blistering denunciation from the FDA of the data that PTC Therapeutics $PTCT has submitted on behalf of its Duchenne muscular dystrophy drug ataluren, a panel of experts voted overwhelmingly against the drug, concluding that it’s still too early to say definitively whether the drug works or not and asking for some hard data from a new study to lay the question to rest once and for all.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.